Investigational drug · Phase 2
EG110A
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neurogenic Detrusor Overactivity, Spinal Cord Injuries, Urinary Bladder, Overactive.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "EG110A"
First trial start
2025
Jan 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EG110A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neurogenic Detrusor Overactivity
- Spinal Cord Injuries
- Urinary Bladder, Overactive
- Spinal Cord Injury
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "EG110A" as an intervention, largest first.
- Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene TherapyNot yet recruiting
Cyllene TherapeuticsIndustry
NCT07227285 · 16 participants (planned) · Start Apr 2026 · Primary completion Apr 2031
Drug: EG110A · For: Urinary Bladder, Overactive; Spinal Cord Injury
Sites: Downey, California; Ann Arbor, Michigan; Philadelphia, Pennsylvania · 4 sites in all
Cyllene TherapeuticsIndustry
NCT06596291 · 16 participants (planned) · Start Jan 8, 2025 · Primary completion Jun 2027
Drug: EG110A · For: Neurogenic Detrusor Overactivity; Spinal Cord Injuries
Sites: Downey, California; Ann Arbor, Michigan; Columbus, Ohio · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.